Reports Q1 revenue $12.31B, consensus $11.92B. “We continue to demonstrate outstanding operational execution and delivered another quarter of strong results,” said Richard Gonzalez, chairman and chief executive officer, AbbVie. “I couldn’t be more proud of the organization we have built over the past 11 years. We’ve established an exemplary company culture, developed a productive R&D engine, delivered top-tier financial performance and made a remarkable impact on patients and the communities we serve.” “I want to thank Rick for his exceptional leadership since AbbVie’s inception and I am deeply honored to serve as the company’s next CEO,” said Robert A. Michael, president and chief operating officer, AbbVie. “First quarter results were well ahead of our expectations, driven by excellent performance from our ex-Humira growth platform. Based on our strong results and significant momentum, we are raising our full-year outlook.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABBV:
- Options Volatility and Implied Earnings Moves Today, April 26, 2024
- Is ABBV a Buy, Before Earnings?
- Options Volatility and Implied Earnings Moves This Week, April 22 – April 26, 2024
- AbbVie reports ‘positive’ results from Phase 3 SELECT-GCA study of upadacitinib
- Fake Botox Fight Sends AbbVie (NASDAQ:ABBV) Up Fractionally